Back to Search Start Over

Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein

Authors :
Abdelhalim Khenchouche
Mounir M. Salem-Bekhit
Ahd A. Mansour
Mohammad N. Alomary
Xiaohui Wang
Hayat Ali Alzahrani
Ibrahim M. Al Hosiny
Ehab I. Taha
Gamal A. Shazly
Yacine Benguerba
Karim Houali
Source :
Microorganisms, Vol 11, Iss 7, p 1712 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

The study aimed to investigate the antitumor efficacy of anti-LMP1 antibodies in EBV-positive nasopharyngeal and stomach cell lines and xenograft models. The study also examined the NF-κB expression and cell cycle activation of NPC-serum-exosome-associated LMP1. Anti-LMP1 antibody treatment before or during cell implantation prevented tumor growth in nude mice. A small dose of antibodies resulted in complete tumor regression for at least three months after the tumors had grown in size. The consumption of antigen–antibody complexes by tumor cells limited tumor growth. In vitro experiments showed that anti-LMP1 antibodies killed EBV-positive NPC- or GC-derived epithelial cell lines and EBV-positive human B-cell lines but not EBV-negative cell lines. Treatment with anti-LMP1 reduced NF-κB expression in cells. The animal model experiments showed that anti-LMP1 inhibited and prevented NPC- or GC-derived tumor growth. The results suggest that LMP1 antibody immunotherapy could cure nasopharyngeal cancer, EBV-positive gastric carcinoma, and EBV-associated lymphomas. However, further validation of these findings is required through human clinical trials.

Details

Language :
English
ISSN :
20762607
Volume :
11
Issue :
7
Database :
Directory of Open Access Journals
Journal :
Microorganisms
Publication Type :
Academic Journal
Accession number :
edsdoj.654315203a4b4227aad5888cf1f783de
Document Type :
article
Full Text :
https://doi.org/10.3390/microorganisms11071712